Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

被引：63

作者：

Gridelli, C ^{[1
]}

Maione, P

Castaldo, V

Rossi, A

机构：

[1] SG Moscati Hosp Via Circumvallaz, Div Med Oncol, I-83100 Avellino, Italy

[2] SG Moscati Hosp Via Circumvallaz, Direz Sanitaria, I-83100 Avellino, Italy

来源：

BRITISH JOURNAL OF CANCER | 2003年 / 89卷 / 10期

关键词：

NSCLC; gefitinib; elderly; poor PS patients;

D O I：

10.1038/sj.bjc.6601387

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Elderly and poor performance status advanced non-small-cell lung cancer ( NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib ( Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate use programme showing some activity and good tolerability.

引用

页码：1827 / 1829

页数：3

共 11 条

[1] Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? [J].

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :23S-33S

[2]

Ciardiello F, 2001, CLIN CANCER RES, V7, P2958

[3] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[4] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[5] Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial [J].

Gridelli, C ;

Perrone, F ;

Gallo, C ;

Cigolari, S ;

Rossi, A ;

Piantedosi, F ;

Barbera, S ;

Ferraù, F ;

Piazza, E ;

Rosetti, F ;

Clerici, M ;

Bertetto, O ;

Robbiati, SF ;

Frontini, L ;

Sacco, C ;

Castiglione, F ;

Favaretto, A ;

Novello, S ;

Migliorino, MR ;

Gasparini, G ;

Galetta, D ;

Iaffaioli, RV ;

Gebbia, V .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05) :362-372

[6] Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group [J].

Gridelli, C ;

Gallo, C ;

Shepherd, FA ;

Illiano, A ;

Piantedosi, F ;

Robbiati, SF ;

Manzione, L ;

Barbera, S ;

Frontini, L ;

Veltri, E ;

Findlay, B ;

Cigolari, S ;

Myers, R ;

Ianniello, GP ;

Gebbia, V ;

Gasparini, G ;

Fava, S ;

Hirsh, V ;

Beziak, A ;

Seymour, L ;

Perrone, F .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3025-3034

[7] Chemotherapy of non-small cell lung cancer in elderly patients [J].

Gridelli, C ;

Maione, P ;

Colantuoni, G ;

Rossi, A .

CURRENT MEDICINAL CHEMISTRY, 2002, 9 (16) :1487-1495

[8]

Herbst R., 2002, P AN M AM SOC CLIN, V21, P292

[9]

MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO

[10]

2-6

← 1 2 →